Abstract Session 4: Genomics

Co-Chair(s)

• 

  Masood Shammas, PhD

  Lead Scientist
  Dana Farber Cancer Institute and VA Boston Healthcare System, Boston, MA, USA
  BOSTON, Massachusetts, United States
• 

  Mark Bustoros, MD

  Assistant Professor Of Medicine
  Meyer Cancer Center, Weill Cornell Medicine, Cornell University
  New York, New York, United States

Presentations:

• 5:15 PM – 5:27 PM EEST

  OA-19: Comprehensive genomic characterization of response and resistance to daratumumab- based quadruplet induction in newly diagnosed multiple myeloma patients
  

  Speaker: Kylee Maclachlan, MBChB, PhD – Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York City NY, USA
• 5:27 PM – 5:39 PM EEST

  OA-16: The rs9344 G risk allele upregulates CCND1 expression through t(11;14) and PAX5 in multiple myeloma
  

  Speaker: Linda B. Baughn, PhD (she/her/hers) – Mayo Clinic, Rochester, MN, US
• 5:39 PM – 5:51 PM EEST

  OA-46: Epigenetic regulation of CD38/48 by KDM6A mediates NK cell response in multiple myeloma
  

  Speaker: Jiye Liu, PhD (he/him/his) – Dana-Farber Cancer Institute
• 5:51 PM – 6:03 PM EEST

  OA-28: Unraveling the heterogeneity of multiple myeloma associated with therapy resistance by single-cell RNA sequencing
  

  Speaker: Takahiro Kamiya, MD (he/him/his) – Division of Stem Cell and Molecular Medicine, Center for Stem Cell Biology and Regenerative Medicine, Institute of Medical Science, The University of Tokyo, Tokyo, Japan / Division of Hematology, Department of Medicine, Keio University School of Medicine, Tokyo, Japan
• 6:03 PM – 6:15 PM EEST

  OA-18: Identification of therapy-induced clonal evolution and resistance pathways in MRD clones in multiple myeloma through single-cell sequencing
  

  Speaker: Jian Cui – Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Science & Peking Union Medical College